the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

By Luke, Jason
Interventional only

Phase III
Study No PI Title
CIRB15-1777 Luke, Jason S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Details
Phase II
Study No PI Title
IRB16-1071 Luke, Jason A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
IRB15-0650 Luke, Jason A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
IRB15-0718 Luke, Jason A Phase II Study of Glembatumumab Vedotin, an AntigpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma (CDX011-05) Details
Phase I
Study No PI Title
IRB16-1735 Luke, Jason A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody Targeting PD1, in Subjects with Advanced Solid Tumors
IRB16-1071 Luke, Jason A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
IRB16-0538 Luke, Jason A Multi-Center, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies Whose Disease has Progressed on PD-1 or PD-L1 Immune Checkpoint Inhibitors Details
IRB15-1561 Luke, Jason A Phase Ia/Ib Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers Details
IRB16-0263 Luke, Jason A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination with Ipilimumab in Patients with B7-H3-expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-small Cell Lung Cancer, and Other B7-H3-Expressing Cancers Details
IRB15-1807 Luke, Jason A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB15-0650 Luke, Jason A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .